BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Average Rating of “Moderate Buy” from Analysts

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $42.60.

Separately, Wall Street Zen lowered BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, June 27th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new position in BioXcel Therapeutics in the first quarter valued at about $50,000. Murchinson Ltd. acquired a new position in shares of BioXcel Therapeutics in the 1st quarter worth approximately $276,000. Squarepoint Ops LLC lifted its holdings in shares of BioXcel Therapeutics by 203.9% in the 4th quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock worth $27,000 after acquiring an additional 48,336 shares during the last quarter. Northern Trust Corp boosted its position in shares of BioXcel Therapeutics by 81.4% during the 4th quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock worth $28,000 after purchasing an additional 33,161 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in BioXcel Therapeutics by 7.5% in the 4th quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock valued at $74,000 after purchasing an additional 13,952 shares during the last quarter. 30.68% of the stock is currently owned by institutional investors and hedge funds.

BioXcel Therapeutics Trading Down 6.1%

Shares of NASDAQ BTAI opened at $1.70 on Thursday. The stock has a market cap of $10.30 million, a PE ratio of -0.13 and a beta of 0.04. BioXcel Therapeutics has a 12-month low of $1.17 and a 12-month high of $19.84. The company has a 50-day moving average of $1.73 and a 200 day moving average of $2.37.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its earnings results on Monday, May 12th. The company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($2.72) by $1.22. The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.35 million. On average, sell-side analysts forecast that BioXcel Therapeutics will post -24.39 EPS for the current fiscal year.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.